文献速递淋巴瘤

以维泊妥珠单抗为基础方案治疗累及中枢神经系统的难治性弥漫大B细胞淋巴瘤:一例病例报告及文献复习

[Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

本文回顾性分析北京医院1例79岁女性难治性继发性中枢神经系统淋巴瘤患者的临床特点及诊治过程,并进行文献复习。患者诊断为弥漫大B细胞淋巴瘤,累及髂骨、骶骨、脊髓、神经根,IPI评分5分,MSKCC评分高风险,老年综合评估(IACA评分)2分,为不适合强化疗组。一线无化疗方案联合放疗后病情进展,二线用以维泊妥珠单抗为基础的方案获得完全缓解,提示该方案可能作为累及中枢神经系统的弥漫大B细胞淋巴瘤患者的治疗选择。

要点

  • 79岁女性弥漫大B细胞淋巴瘤患者,累及髂骨、骶骨、脊髓、神经根,IPI评分5分,MSKCC评分高风险。
  • 老年综合评估(IACA评分)2分,归为不适合强化疗组。
  • 一线无化疗方案联合放疗后进展,二线以维泊妥珠单抗为基础方案获得完全缓解。

核心结论

  • 以维泊妥珠单抗为基础的方案可能作为累及中枢神经系统的弥漫大B细胞淋巴瘤患者的治疗选择。

研究设计与样本

  • 回顾性分析北京医院1例脊髓受累的难治性继发性中枢神经系统淋巴瘤患者的临床特点及诊治过程,并进行相关文献复习。
  • 患者为79岁女性,诊断为弥漫大B细胞淋巴瘤,累及髂骨、骶骨、脊髓、神经根,IPI评分5分,MSKCC评分高风险,老年综合评估(IACA评分)2分,为不适合强化疗组。

主要发现

  • 一线治疗应用无化疗方案联合放疗,患者病情进展。
  • 二线治疗应用以维泊妥珠单抗为基础的方案,患者获得完全缓解。

临床怎么用

  • 作者认为以维泊妥珠单抗为基础的方案可能作为累及中枢神经系统的弥漫大B细胞淋巴瘤患者的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polatuzumab vedotin (Pola) is a novel antibody-drug conjugate targeting CD79b, which has been shown to be effective in treating newly diagnosed and relapsed/refractory diffuse large B cell lymphoma (DLBCL) during clinical trials. This study aims to conduct a retrospective analysis of the clinical characteristics, diagnosis, and treatment of a patient with refractory secondary central nervous system lymphoma at Beijing Hospital, alongside a review of relevant literature. This study included a 79-year-old female patient who was diagnosed with DLBCL affecting the ilium, sacrum, spinal cord, and nerve roots and had an IPI score of 5 and a high-risk score according to MSKCC. She showed a geriatric comprehensive assessment (IACA) score of 2, which was categorized under the unfit group. Her initial treatment comprised chemo-free therapy and radiotherapy, followed by progression. In the second-line treatment, a Pola-based regimen was applied, and the patient achieved a complete response, suggesting that this regimen may be a therapeutic option for patients with DLBCL involving the central nervous system. 维泊妥珠单抗(Pola)是一种靶向CD79b的新型抗体药物偶联物,临床试验显示在初诊和复发/难治的弥漫大B细胞淋巴瘤(DLBCL)中均有效。本文回顾性分析了北京医院1例脊髓受累的难治性继发性中枢神经系统淋巴瘤患者的临床特点及诊治过程,并进行相关文献复习。患者79岁,诊断为DLBCL,累及髂骨、骶骨、脊髓、神经根,IPI评分5分,MSKCC评分高风险,老年综合评估(IACA评分)2分,为不适合强化疗组。一线治疗应用无化疗方案联合放疗,患者病情进展,二线治疗应用以Pola为基础的方案,患者获得完全缓解,提示Pola可能作为累及中枢神经系统的DLBCL患者的治疗选择。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Bai JF, Feng R, Wang T, et al. [Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39414613. doi:10.3760/cma.j.cn121090-20240119-00035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。